Substance and claimed effects

Chronic kidney disease (CKD) stages G1 through G3a covers the early-disease window: estimated glomerular filtration rate (eGFR) from above 90 down to 45 mL/min/1.73m2, with or without albuminuria (urine albumin-to-creatinine ratio, uACR), persisting for at least three months KDIGO 2024. Roughly 10–14% of the adult population worldwide meets these criteria, and most do not know it Hill et al. 2016. The first 90 days after diagnosis are the high-leverage window in which several decisions reset the disease trajectory: confirming the diagnosis (a one-off bad creatinine is not CKD), staging by both eGFR and albuminuria, ruling out reversible causes, starting renin-angiotensin-system (RAS) blockade and an SGLT2 inhibitor where indicated, and aligning cardiovascular-risk control around a population that dies of heart disease far more often than it dies of kidney failure Go et al. 2004. The substance is the early-CKD diagnosis itself and the orchestrated package of testing, classification, and disease-modifying therapy that follows in the first three months. Consequences span longevity (cardiovascular and kidney mortality), short-term health (symptom control, drug safety review), mood (the anxiety of a CKD diagnosis without intervention vs. a clear plan), and a real but bounded effort and cost burden (clinician visits, daily medications, blood pressure self-monitoring). Beauty and sleep are not first-order consequences at this stage.

Evidence by addressing question

mechanism

CKD G1–G3a is defined by structural or functional kidney damage that has persisted for at least three months. The two markers are eGFR (filtration capacity) and albuminuria (the kidney's barrier leaking protein into urine). Stages map to eGFR bands: G1 is ≥90 with structural damage or albuminuria, G2 is 60–89 with damage, G3a is 45–59 KDIGO 2024. Albuminuria is staged separately as A1 (uACR <30 mg/g), A2 (30–300), A3 (>300). The two axes are multiplicative on risk, not additive — a G2 A3 patient has roughly the cardiovascular and progression risk of a G3b A1 patient Matsushita et al. 2010.

Mechanistically, the dominant driver of progression across most causes (diabetic, hypertensive, glomerular) is glomerular hyperfiltration: surviving nephrons compensate for lost ones by filtering harder, which is adaptive short-term and destructive long-term. The angiotensin-II–mediated constriction of the efferent arteriole sustains this pressure; blocking that constriction with an ACE inhibitor or ARB lowers intraglomerular pressure, drops albuminuria within weeks, and slows decline over years Brenner et al. 2001 Lewis et al. 2001. SGLT2 inhibitors act on the afferent arteriole via tubuloglomerular feedback: blocking glucose-and-sodium reabsorption in the proximal tubule increases distal sodium delivery, the macula densa senses this and constricts the afferent arteriole, intraglomerular pressure falls, and an early 3–5 mL/min/1.73m² drop in eGFR appears within weeks — followed by a markedly slower long-term decline Cherney et al. 2017. This initial drop is mechanistic, not toxic.

Cardiovascular risk in early CKD is not primarily from uremia (G1–G3a patients are not uremic). It is from accelerated atherosclerosis driven by chronic inflammation, dyslipidemia, vascular calcification, and the same albuminuria that signals kidney damage signals endothelial dysfunction throughout the vasculature Matsushita et al. 2010.

evidence

The Go et al. 2004 cohort of 1.1 million adults established the foundational fact: as eGFR drops below 60, age-adjusted rates of death, cardiovascular events, and hospitalization rise steeply — and most patients die of cardiovascular disease before reaching dialysis Go et al. 2004. The Matsushita 2010 meta-analysis (1.5 million participants across 21 general-population cohorts) made the case for albuminuria as an independent multiplier of mortality risk on top of eGFR, formalized in the KDIGO heat map Matsushita et al. 2010.

For RAS blockade, RENAAL (losartan in type 2 diabetic nephropathy) showed a 16% reduction in the composite of doubling of creatinine, end-stage renal disease, or death Brenner et al. 2001, and IDNT (irbesartan, same population) replicated this Lewis et al. 2001. The Jafar 2003 AIPRD individual-patient meta-analysis extended ACE inhibitor benefit to non-diabetic proteinuric CKD Jafar et al. 2003. The effect concentrates in albuminuric patients — A2 and above.

SGLT2 inhibitors are the dominant new evidence. CREDENCE (canagliflozin, n=4,401, type 2 diabetes with albuminuric CKD) was stopped early for efficacy: 30% relative reduction in the primary composite of end-stage kidney disease, doubling of serum creatinine, or renal or cardiovascular death (hazard ratio 0.70, 95% CI 0.59–0.82) Perkovic et al. 2019. DAPA-CKD (dapagliflozin, n=4,304, with and without diabetes) showed a 39% relative reduction in the primary composite of sustained ≥50% eGFR decline, end-stage kidney disease, or renal/cardiovascular death (HR 0.61, 95% CI 0.51–0.72) with consistent effect regardless of diabetes status Heerspink et al. 2020 Chertow et al. 2021. EMPA-KIDNEY (empagliflozin, n=6,609, the broadest CKD population to date, including patients without diabetes and without significant albuminuria) showed a 28% relative reduction in the primary composite of kidney disease progression or cardiovascular death (HR 0.72, 95% CI 0.64–0.82) Herrington et al. 2023. The Nuffield 2022 collaborative meta-analysis of 13 trials confirmed the benefit holds across diabetic and non-diabetic CKD SMART-C 2022.

For non-steroidal mineralocorticoid receptor antagonism, FIDELIO-DKD (finerenone, n=5,734) showed an 18% relative reduction in kidney composite endpoints in type 2 diabetes with CKD already on maximal RAS blockade Bakris et al. 2020, and FIGARO-DKD (same drug, n=7,437, broader CKD severity) showed cardiovascular benefit with a 13% reduction in the cardiovascular composite Pitt et al. 2021. For GLP-1 receptor agonists, FLOW (semaglutide, n=3,533, type 2 diabetes with CKD) showed a 24% relative reduction in the primary kidney-disease composite (HR 0.76, 95% CI 0.66–0.88), establishing GLP-1 agonists as a fourth disease-modifying pillar alongside ACEi/ARB, SGLT2 inhibitors, and finerenone Perkovic et al. 2024.

For blood pressure, SPRINT (n=9,361, non-diabetic high-CV-risk adults including ~28% with CKD) showed that targeting systolic BP <120 mmHg reduced cardiovascular events by 25% and all-cause mortality by 27% versus <140 mmHg, at the cost of more acute kidney injury and hypotension SPRINT 2015. KDIGO 2024 endorses a target systolic of <120 mmHg in most CKD patients tolerating it KDIGO 2024.

protocol

The KDIGO 2024 first-90-days workup, condensed KDIGO 2024:

• Confirm chronicity. A single abnormal creatinine is not CKD. Repeat eGFR and uACR at ≥3 months from the index test. Acute kidney injury, dehydration, NSAID use, and high-protein meals all transiently affect creatinine.
• Use the 2021 race-free CKD-EPI equation for eGFR — the prior equation's race coefficient is no longer recommended Inker et al. 2021. When the creatinine-based eGFR is borderline (45–59) and the clinical stakes are high (e.g. drug dosing, donor candidacy), confirm with cystatin C.
• Stage on both axes. eGFR (G1–G5) and albuminuria (A1–A3). The KDIGO risk heat map (green / yellow / orange / red) is the right object to act on, not eGFR alone.
• Workup the cause. Diabetes status, blood pressure history, family history (autosomal dominant polycystic kidney disease, Alport syndrome), medication review (NSAIDs, lithium, PPIs, calcineurin inhibitors), urinalysis for hematuria, renal ultrasound if obstruction or polycystic disease is plausible. Glomerular causes (rapid decline, hematuria with proteinuria, systemic features) warrant nephrology referral early.
• Calculate kidney-failure risk. The Tangri Kidney Failure Risk Equation (KFRE) gives a 2- and 5-year probability of kidney failure using age, sex, eGFR, and uACR; a 5-year risk >5% is the standard nephrology-referral threshold Tangri et al. 2016.
• Start an ACEi or ARB at low dose if uACR is >30 mg/g (especially >300) or if blood pressure is uncontrolled. Titrate to maximum tolerated dose. Recheck potassium and creatinine within 2–4 weeks; an initial creatinine bump of up to 30% is expected and not a reason to stop Bakris et al. 2020.
• Start an SGLT2 inhibitor (dapagliflozin or empagliflozin) if eGFR is ≥20, regardless of diabetes status, and especially if uACR is ≥200 mg/g Heerspink et al. 2020 Herrington et al. 2023. Expect a 3–5 mL/min eGFR drop in the first month and ignore it.
• Blood pressure target <120 mmHg systolic (standardized office measurement), in most patients who tolerate it SPRINT 2015 KDIGO 2024.
• Statin for cardiovascular risk in essentially all CKD adults ≥50, regardless of LDL KDIGO 2024.
• HbA1c target ~7% if diabetic, individualized; consider GLP-1 agonist (semaglutide) for additional kidney and cardiovascular protection Perkovic et al. 2024.
• Lifestyle: sodium <2 g/day, smoking cessation, moderate protein intake (0.8 g/kg/day; not the high-protein diets often promoted for muscle gain), maintain physical activity.
• Avoid nephrotoxins: chronic NSAIDs, contrast where alternatives exist, herbal supplements with documented nephrotoxicity (aristolochic acid).

contraindications

RAS blockers (ACEi/ARB): pregnancy (absolute), bilateral renal artery stenosis, hyperkalemia >5.5 mmol/L not correctable. A >30% creatinine rise within 2–4 weeks of starting suggests volume depletion or renal artery disease and warrants dose reduction or pause. ACEi/ARB combination is not recommended (ONTARGET-era data: more harm than benefit).

SGLT2 inhibitors: type 1 diabetes (DKA risk), recurrent UTI or genitourinary infections (genital mycotic infections are the main side effect), volume depletion. Hold during acute illness with reduced oral intake to prevent euglycemic DKA. Foot ulcers and amputation risk was a CANVAS-era signal that has not held up in subsequent trials but warrants attention in advanced peripheral vascular disease.

Finerenone: hyperkalemia, concurrent strong CYP3A4 inhibitors (itraconazole), severe hepatic impairment. Monitor potassium at 4 weeks then periodically.

Metformin: traditionally held below eGFR 30 (lactic acidosis concern); usable down to eGFR 30 with dose reduction below 45.

misconceptions

The widely repeated misconceptions in primary care and among patients:

• "My creatinine is normal so my kidneys are fine." Creatinine is insensitive at the early-CKD range — substantial nephron loss can occur before creatinine moves outside the lab's reference interval, particularly in older or low-muscle-mass patients Eknoyan et al. 2009.
• "The eGFR dropped after starting the new drug — stop it." A 3–5 mL/min initial drop after ACEi/ARB or SGLT2 is mechanistic and predicts long-term benefit. The drugs that look like they're harming the kidney short-term are the ones preserving it long-term Cherney et al. 2017.
• "SGLT2 inhibitors are diabetes drugs." They started as glucose-lowering agents and ended up as kidney and heart drugs that happen to lower glucose. DAPA-CKD and EMPA-KIDNEY both enrolled non-diabetic patients and showed effect Heerspink et al. 2020 Herrington et al. 2023.
• "Low-protein diet halts progression." Modest protein restriction (0.8 g/kg/day) is reasonable; very-low-protein diets are not supported by modern trial evidence in early CKD and risk malnutrition. The MDRD trial's signal was modest at best.
• "Most CKD progresses to dialysis." Most G1–G3a patients die of cardiovascular disease before reaching dialysis Go et al. 2004. Early management is as much cardiovascular as renal.
• "Hydration prevents progression." Adequate hydration is fine; aggressive water intake offers no proven kidney protection and can cause hyponatremia in vulnerable patients.

audience

Roughly 14% of US adults have CKD; the majority are at G1–G3a and undiagnosed Hill et al. 2016. Sub-populations with meaningful protocol differences:

• Diabetic patients: the highest-yield subgroup for SGLT2 and GLP-1 agonist therapy. Should be screened with eGFR + uACR annually KDIGO 2024.
• Hypertensive patients: RAS blockade serves both blood pressure and renal protection.
• Older adults: mild eGFR reduction (60–75) is common with aging. KDIGO maintains the same definition regardless of age but emphasizes that risk is the multiplied function of eGFR and albuminuria — a 65-year-old with eGFR 55 and uACR <10 is at low risk; the same eGFR with uACR 200 is high.
• Pregnant patients: ACEi/ARB and SGLT2 contraindicated; specialist co-management.
• Black patients: the 2021 CKD-EPI equation removed the race coefficient, which had been overestimating eGFR in Black patients and delaying diagnosis and treatment Inker et al. 2021.
• Family-history of polycystic kidney disease: ultrasound screening; tolvaptan eligibility consideration.

failure-modes

What goes wrong in practice, by frequency:

• Missed diagnosis from creatinine alone. Without uACR, A3 albuminuria patients with preserved eGFR are missed — and these are some of the highest-risk patients Matsushita et al. 2010.
• Drug-stop reflex. ACEi/ARB or SGLT2 stopped after the expected initial creatinine bump, losing the long-term protection.
• No nephrology referral. KFRE 5-year risk >5%, eGFR <30, persistent uACR >300, rapid decline (>5 mL/min/year), unexplained hematuria — all warrant referral; many get sat on Tangri et al. 2016.
• NSAID re-exposure. The patient is told "no ibuprofen," then takes it for a headache. The cumulative dose matters.
• Contrast catastrophes. Imaging departments not flagging eGFR before contrast administration; usually preventable.
• Anxiety + lifestyle paralysis. The patient is told they have "kidney disease," interprets it as imminent dialysis, restricts protein and water inappropriately, becomes malnourished and dehydrated.
• Therapeutic inertia. The biggest one: the cardiologist/PCP doesn't add SGLT2 because "that's for diabetes" or "that's for nephrology to decide." Practice is years behind trial evidence in primary care.

practicalities

Cost: a chemistry panel and uACR cost roughly $20–50 retail, less through insurance. ACEi/ARBs (lisinopril, losartan) are generic and cost <$50/year. SGLT2 inhibitors are still branded in most markets — dapagliflozin (Farxiga) and empagliflozin (Jardiance) run roughly $500–$600/month US retail, with insurance and patient-assistance often dropping that to $0–$50 copay; generic empagliflozin entered some markets in 2025. Finerenone (Kerendia) is similarly branded and pricey. Generic statins are cheap. Home blood pressure cuff: $40–80 one-time.

Time burden in the first 90 days: typically two primary care visits, one set of labs, one nephrology visit if criteria met. Ongoing: labs every 3–6 months in stable disease, more often during titration. The protocol is straightforward to administer and the inertia is the binding constraint, not complexity.

stakes

Without intervention, the trajectory across years for a G2–G3a patient with albuminuria is faster eGFR decline (3–5 mL/min/year vs. the age-expected ~1) and substantially elevated cardiovascular risk. The mortality multiplier in the Go et al. cohort: vs. a person with eGFR ≥60, an adult with eGFR 45–59 has roughly 1.2× all-cause mortality, eGFR 30–44 has 1.8×, eGFR 15–29 has 3.2×; cardiovascular event rates roughly double across the same range Go et al. 2004. Albuminuria is independently and multiplicatively bad Matsushita et al. 2010. Most die of cardiovascular events, not of kidney failure; among the minority who do reach dialysis, life expectancy is roughly 5–10 years and quality of life is profoundly reduced.

payoff

With SGLT2 + RAS blockade + BP control started in early CKD, the trial-level eGFR slope flattens by 1–2 mL/min/year and the time to halving of kidney function or dialysis extends by years. The DAPA-CKD primary endpoint hazard ratio of 0.61 translates roughly to: 19 patients treated for 2.4 years to prevent one major adverse kidney event; numbers-needed-to-treat for SGLT2 inhibitors in CKD are among the lowest in cardiovascular medicine Heerspink et al. 2020. Cardiovascular events drop in parallel — the same drugs preventing kidney progression also prevent heart failure hospitalization. Subjectively, most G1–G3a patients are asymptomatic at baseline and remain so on treatment; the felt change is mostly the absence of the bad future. Some patients experience genuine symptom improvement from better blood pressure control (less headache, less fatigue) and from albuminuria reduction.

out-of-scope

G3b–G5 management (advanced CKD), dialysis modality choice, transplant workup, anemia of CKD (EPO, iron), bone-mineral disease (calcium, phosphate, vitamin D analogs, PTH), specific glomerular diseases requiring immunosuppression, and pediatric CKD all sit beyond the early-disease window this entry covers.

The credibility range

Optimist case

Early CKD is one of the cleanest stories in modern internal medicine. Multiple large, placebo-controlled, blinded RCTs across SGLT2 inhibitors (CREDENCE, DAPA-CKD, EMPA-KIDNEY), RAS blockers (RENAAL, IDNT, AIPRD), GLP-1 agonists (FLOW), and finerenone (FIDELIO, FIGARO) consistently show 20–40% relative risk reductions in kidney-disease progression and cardiovascular events, with effects replicated across diabetic and non-diabetic populations, across geographies, and across the spectrum of CKD severity. The 2024 KDIGO guideline integrates these into a coherent algorithm. Mechanism is well-understood (hemodynamic effects on intraglomerular pressure plus metabolic and inflammatory benefits). When started early — before substantial nephron loss — the trajectory of the disease genuinely bends. The intervention is cheap (most drugs are or will soon be generic), well-tolerated, and the protocol is teachable to primary care. The main remaining problem is implementation: getting the drugs to the patients who would benefit.

Skeptic case

The trials enrolled selected populations: most participants were already on a stable ACEi/ARB, were adherent enough to complete a screening run-in, had a uACR threshold that excluded the bulk of low-albuminuria CKD (true for CREDENCE and DAPA-CKD), and were followed for 2–3 years — not the 10–30 years of natural disease history. EMPA-KIDNEY's broader enrollment is the partial answer. The eGFR-slope endpoints are surrogates; hard endpoints (dialysis, death) accrue more slowly. Absolute risk reductions, though clinically meaningful, are smaller than the relative reductions imply — the number needed to treat is reasonable but not heroic. The intensive blood pressure target from SPRINT excluded diabetics and used standardized unattended office measurements that translate imperfectly to clinic-cuff readings; pushing to <120 systolic in routine practice produces more falls, more electrolyte disturbances, and more drug interactions than in the trial. Polypharmacy in older CKD patients (RAS blocker, SGLT2, finerenone, statin, antihypertensive, antidiabetic) is genuinely complex and the trial data on combined four-pillar therapy is thinner than the marketing implies. Industry funded the major SGLT2 and finerenone trials and the speed of guideline uptake reflects that. None of this overturns the basic finding; it tempers the magnitude.

Author's call

This is settled science with a strong, well-replicated effect, and the dominant clinical failure is undertreatment, not overtreatment. The first 90-day protocol — confirm with repeat labs, stage on both eGFR and albuminuria, start ACEi/ARB and SGLT2 inhibitor where indicated, BP <120, statin, refer to nephrology when KFRE flags risk — should be considered standard of care for any patient meeting CKD G1–G3a criteria. The skeptic-case nuances matter at the margins (BP target in frail elderly, drug interactions, surrogate-vs-hard-endpoint translation) but do not change the broad strokes. Evidence rating: 5. Controversy rating: 1 — the major debates (race-free eGFR adoption, BP target tightness in elderly) are operational details, not paradigm fights.

Stakeholder and incentive map

• Pharmaceutical industry (AstraZeneca for dapagliflozin, Boehringer Ingelheim/Lilly for empagliflozin, Janssen for canagliflozin, Bayer for finerenone, Novo Nordisk for semaglutide): funded the major trials, push for early and broad initiation. Trials are well-conducted but readers should expect that effect sizes presented in industry slide decks emphasize relative over absolute.
• Nephrology professional bodies (KDIGO, ASN, ERA): broadly aligned with industry on early initiation; KDIGO 2024 is the consensus document and reflects independent literature synthesis.
• Primary care organizations (AAFP, ACP): generally adopt KDIGO with delay; implementation gap is the dominant problem.
• USPSTF: historically conservative on CKD screening in asymptomatic adults (current grade: insufficient evidence for general-population screening) USPSTF 2012. This is a real point of friction with nephrology, which advocates targeted screening of diabetic and hypertensive populations.
• Patient advocacy (National Kidney Foundation, American Kidney Fund): aligned with early-intervention messaging.
• Payers: split — SGLT2 cost has been a friction point, dropping as generics emerge.

Population variability

• Diabetes status: SGLT2 benefit is consistent in diabetic and non-diabetic CKD per DAPA-CKD subgroup analysis and the SMART-C meta-analysis Chertow et al. 2021 SMART-C 2022.
• Albuminuria status: RAS blockade benefit concentrates in albuminuric patients (A2/A3); benefit in normoalbuminuric CKD is small. SGLT2 benefit extends to lower albuminuria thresholds than RAS blockers (EMPA-KIDNEY enrolled down to A1 with eGFR 20–45) Herrington et al. 2023.
• Age: trials enrolled patients mostly under 80; effect sizes in the >80 group are inferred. Frailty changes the calculus on aggressive BP control.
• Race/ethnicity: Black patients have higher CKD prevalence and faster progression; the removal of the race coefficient in eGFR calculation in 2021 is a structural correction of underdiagnosis Inker et al. 2021.
• Underlying cause: diabetic and hypertensive CKD dominate the trial populations; effect in autosomal dominant polycystic kidney disease (ADPKD), IgA nephropathy, lupus nephritis is being studied but less established.
• Sex: men have somewhat faster progression on average; both sexes benefit equivalently from disease-modifying therapy.

Knowledge gaps

• Optimal sequencing and combination of the four pillars (RAS blocker, SGLT2 inhibitor, GLP-1 agonist, finerenone) is not formally tested head-to-head; current practice is layer-on-tolerance.
• Long-term (>5-year) hard-endpoint data for SGLT2 inhibitors in non-diabetic CKD is still maturing.
• Whether the SPRINT <120 BP target translates to frail elderly CKD patients with attended-cuff measurement is uncertain.
• The role of population screening for early CKD remains a USPSTF-vs-nephrology disagreement that better screening tests or treatment effect sizes might resolve.
• Effect of SGLT2 inhibitors in advanced CKD (eGFR <20) and in specific glomerular diseases is being studied.
• Implementation science: the gap between guideline and practice is the dominant problem, and what shifts primary-care prescribing behavior is poorly understood.

Scope vs brief. The brief named four consequences: disease progression, cardiovascular risk, SGLT2 inhibitors, and "other disease-modifying therapy." All four are covered. SGLT2 inhibitors get the most space because the evidence base shifted most recently there; RAS blockade, BP control, finerenone, GLP-1 agonists, and statin use are all in the article.

Action type. Set to decide rather than do because every drug here is prescription-only and the protocol requires clinician coordination. Cadence is course — the 90-day window is the defined endpoint of this entry, even though the resulting daily medication regimen is lifelong (a separate downstream entry could cover long-term CKD management).

Beauty/sleep/focus scored 0. Early CKD has no meaningful direct effects on these dimensions. Scoring them non-zero would be reaching.

Energy scored 1 not 2. Most early-CKD patients are asymptomatic so the felt-energy improvement is rare; the score reflects the small subgroup who feel sharper once BP is properly controlled.

Mood scored 2. Conservative call. The clinical-anxiety literature on CKD diagnosis is real but the magnitude of relief from a clear plan is modest, not transformative.

Cost scored 2 not 3. Lands on the boundary. SGLT2 inhibitors at full retail would justify a 3, but the typical insured-patient experience lands in the 2 band ($50-$500/year). Flagged as a possible re-rate once empagliflozin is broadly generic.

Contraindications. Only pregnancy is on the closed vocabulary list and clearly applies to the whole protocol (ACEi/ARB and SGLT2 both contraindicated). Type 1 diabetes is mentioned in the article but not in the closed vocabulary. Eating-disorder-history, diabetes-medication, etc. don't apply at the entry level.

USPSTF screening debate. Mentioned in the dossier but kept out of the article body to avoid distraction — the entry is for someone who already has a borderline result, not for the general-screening decision.

Separate-entry candidates:

• Advanced CKD management (G3b-G5) — own entry; different protocol, different stakes.
• Dialysis modality decision — own entry, decide-action, specialist territory.
• Home blood pressure measurement technique — narrow how-to entry, would link from this one.
• Statin for primary cardiovascular prevention — own entry, broader than CKD.
• SGLT2 inhibitors in heart failure (without CKD) — own entry, different evidence base.

Future-link candidates: statins, home BP monitoring, advanced CKD, smoking cessation, sodium intake, sustained physical activity, NSAIDs.

Hard call: the <120 systolic BP target. SPRINT-derived, endorsed by KDIGO 2024, but the trial used standardized unattended office measurements that translate imperfectly to typical clinic readings, and excluded diabetics and frail elderly. Wrote the recommendation in the protocol as the KDIGO target and flagged the frailty caveat in contraindications rather than hedging the headline number. Reviewer may want to revisit.